Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript

SA Transcripts158.91K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Axsome Therapeutics, Inc. (AXSM) Leerink Global Healthcare Conference 2026 March 9, 2026 4:20 PM EDT Company Participants Nick Pizzie - Chief Financial OfficerMark Jacobson - Chief Operating Officer Conference Call Participants Marc Goodman - Leerink Partners LLC, Research Division Presentation Marc GoodmanLeerink Partners LLC, Research Division Thanks, everybody, for joining. Sorry we're a little late. logistical issues, but we're good. I'm Marc Goodman, one of the biopharma analysts at Leerink, and we're lucky enough to have Axsome Therapeutics with us. And we have Mark Jacobson, who's the COO; and Nick Pizzie, who's the CFO. Thanks, guys, for joining us. Question-and-Answer Session Marc GoodmanLeerink Partners LLC, Research Division So why don't we just start with Auvelity and just give us kind of a little bit of a load down on what's happening with Auvelity right now, just from a marketing strategy perspective, how you're thinking about things this year relative to what you were doing last year and the year before? What's changing? Nick PizzieChief Financial Officer Sure. Yes. Maybe I'll start. Thanks for having us, Marc. So Auvelity ended the year last year, annualizing just north of $600 million, and it is the third full year since launch in 2022. So really pleased with the performance. We're outpacing some of the peers in the space. So very pleased with that. And that was with, I'll say, a smaller field force. We started with 160, did an expansion in '24 to 260 and then got to the most recent levels of 300 in 2025. And also with market access, that has evolved and improved over time. And currently, we're at 86% coverage. So been pleased with the performance from a revenue perspective and script growth. One of the things that we are doing in 2026 is expanding the